Search

Displaying results 3341 - 3350 of 10000 in total
  1. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. … The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.

    Synonyms: 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acidProducts: E-ZOX
  2. Drug

    Mitoxantrone

    go.drugbank.com/drugs/DB01204
    ApprovedInvestigational

    An anthracenedione-derived antineoplastic agent.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index
  3. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. … Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors.

  4. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin E immune FAB2 (equine), BOTULINUM NEUROTOXIN E IMMUNE FAB2, EQUINE
  5. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

  6. Target

    Lysine-specific histone demethylase 1A

    go.drugbank.com/bio_entities/BE0010091
    TargetHumans

    Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development (PubMed:16079794, PubMed:16140033

    Synonyms: BRAF35-HDAC complex protein BHC110
  7. Drug

    Dienestrol

    go.drugbank.com/drugs/DB00890
    ApprovedWithdrawn

    Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. … Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva.

  8. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues … Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer.

  9. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].

  10. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.